science
U.S. Updates Hepatitis B Vaccine Guidelines to Target Newborns at Risk of Infection
A new U.S. policy limits hepatitis B vaccine recommendations at birth to babies at risk of neonatal infection. Separately, Intellia Therapeutics reported positive trial results for its CRISPR treatment, and federal regulators announced new pathways for device coverage and psychedelics reviews. The Trump administration warned against federal funding for fentanyl test strips.
upi.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
U.S. policy recommends offering the hepatitis B vaccine at birth only to babies perceived to be at risk of neonatal infection. The announcement, published three hours ago, marks a shift in vaccination guidelines.
@statnews reported that studies project dire consequences from this change. Intellia Therapeutics announced on Monday that a single dose of its CRISPR-based gene editing treatment reduced swelling attacks in patients with a rare disease in a pivotal trial. The company detailed dramatic reductions in attacks following the treatment.
This update was published 13 hours ago. Federal regulators announced on Thursday a new Medicare coverage pathway for devices deemed breakthroughs by the Food and Drug Administration.
@statnews reported the announcement four days ago. The FDA will speed up review of three psychedelics as mental health treatments. This decision aims to accelerate evaluations for potential therapeutic uses.
The Trump administration issued an open letter on April warning against using federal dollars on fentanyl test strips. The administration is opposing harm reduction services for people who use illicit drugs.
Sen. ) asked health secretary Robert F. Kennedy Jr. last week whether he would release a contract by Friday. Democrats state that Robert F. Kennedy Jr. has a pattern of failing to answer their questions.
